Since PKM2 has also been reported to promote HIF-1α-mediated activation of glucose metabolism-related genes, including GLUT1, in cancer cells [23], it was rational to hypothesize that PKM2 might play a pivotal role in the acquired resistance to erlotinib and aggressive phenotype of OSCC. The gene discussed is PKM; the disease is cancer.